RT Journal Article SR Electronic T1 Immune response to SARS-CoV-2 in the nasal mucosa in children and adults JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.26.21250269 DO 10.1101/2021.01.26.21250269 A1 Clarissa M Koch A1 Andrew D Prigge A1 Kishore R Anekalla A1 Avani Shukla A1 Hanh Chi Do-Umehara A1 Leah Setar A1 Jairo Chavez A1 Hiam Abdala-Valencia A1 Yuliya Politanska A1 Nikolay S Markov A1 Grant R Hahn A1 Taylor Heald-Sargent A1 L Nelson Sanchez-Pinto A1 William J Muller A1 Alexander V Misharin A1 Karen M Ridge A1 Bria M Coates YR 2021 UL http://medrxiv.org/content/early/2021/01/28/2021.01.26.21250269.abstract AB Rationale Despite similar viral load and infectivity rates between children and adults infected with SARS-CoV-2, children rarely develop severe illness. Differences in the host response to the virus at the primary infection site are among the proposed mechanisms.Objectives To investigate the host response to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.Methods Clinical outcomes and gene expression in the nasal mucosa were analyzed in 36 children hospitalized with SARS-CoV-2 infection, 24 children with RSV infection, 9 children with IV infection, 16 adults with mild to moderate SARS-CoV-2 infection, and 7 healthy pediatric and 13 healthy adult controls.Results In both children and adults, infection with SARS-CoV-2 leads to an interferon response in the nasal mucosa. The magnitude of the interferon response correlated with the abundance of viral reads and was comparable between symptomatic children and adults infected with SARS-CoV-2 and symptomatic children infected with RSV and IV. Cell type deconvolution identified an increased abundance of immune cells in the samples from children and adults with a viral infection. Expression of ACE2 and TMPRSS2 – key entry factors for SARS-CoV-2 – did not correlate with age or presence or absence of viral infection.Conclusions Our findings support the hypothesis that differences in the immune response to SARS-CoV-2 determine disease severity, independent of viral load and interferon response at the primary infection primary site.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAndrew D. Prigge was supported by the Gorter Family Foundation. Alexander V. Misharin was supported by N.I.H. grants U19AI135964, P01AG049665, R01HL153312, and NUCATS COVID-19 Rapid Response Grant. Karen M. Ridge was supported by N.I.H. grants P01AG049665 and P01GM096971. Bria M. Coates was supported by funds provided by the Manne Research Institute COVID-19 Springboard Exploratory Research Award and N.I.H. grant K08HL143127. Taylor Heald-Sargent and L. Nelson Sanchez- Pinto were supported by funds provided by the Manne Research Institute COVID-19 Springboard Exploratory Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ann & Robert H. Lurie Childrens Hospital of Chicago, Office of Research Integrity and Compliance, Institutional Review Board. Approval given (not waived)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed RNA-seq counts are available as Online Supplemental Table 1. Raw data is in the process of being deposited to dbGaP/SRA. Code is available via https://github.com/NUPulmonary/2021_Koch.